{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:27:54Z","timestamp":1787725674200,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1208\/s12249-019-1332-0","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:04:01Z","timestamp":1551719041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells"],"prefix":"10.1208","volume":"20","author":[{"given":"Ketan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Doddapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Patki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanthkumar","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"2","key":"1332_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14737140.2017.1266265","volume":"17","author":"W Br\u00fcckl","year":"2017","unstructured":"Br\u00fcckl W, Tufman A, Huber RM. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther. 2017;17(2):143\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1332_CR2","first-page":"36","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1332_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2217\/nnm.16.37","volume":"11","author":"K Patel","year":"2016","unstructured":"Patel K, Doddapaneni R, Chowdhury N, Boakye CH, Behl G, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomed (Lond). 2016;11(11):1377\u201392.","journal-title":"Nanomed (Lond)"},{"key":"1332_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fmed.2016.00076","volume":"3","author":"I Sullivan","year":"2017","unstructured":"Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med. 2017;3:76.","journal-title":"Front Med"},{"key":"1332_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1634\/theoncologist.2015-0209","volume":"21","author":"GD Goss","year":"2016","unstructured":"Goss GD, Spaans JN. Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung. Oncologist. 2016;21:205\u201313.","journal-title":"Oncologist"},{"issue":"1","key":"1332_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"S-G Wu","year":"2018","unstructured":"Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.","journal-title":"Mol Cancer"},{"issue":"3","key":"1332_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ijc.25367","volume":"128","author":"A Biran","year":"2011","unstructured":"Biran A, Brownstein M, Haklai R, Kloog Y. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer. 2011;128(3):691\u2013701.","journal-title":"Int J Cancer"},{"key":"1332_CR8","doi-asserted-by":"crossref","unstructured":"Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, et al. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Ther. 2011.","DOI":"10.1016\/S0923-7534(20)32199-2"},{"issue":"5","key":"1332_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1188\/18.CJON.542-548","volume":"22","author":"R Edwards","year":"2018","unstructured":"Edwards R, Andan C, Lalla R, Lacouture M, O'Brien D, Sequist L. Afatinib therapy: practical management of adverse events with an oral agent for non-small cell lung cancer treatment. Clin J Oncol Nurs. 2018;22(5):542\u20138.","journal-title":"Clin J Oncol Nurs"},{"issue":"8","key":"1332_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161233","volume":"11","author":"DA Ruess","year":"2016","unstructured":"Ruess DA, Probst M, Marjanovic G, Wittel UA, Hopt UT, Keck T, et al. HDACi valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) delay but fail to protect against warm hepatic ischemia-reperfusion injury. PLoS One. 2016;11(8):e0161233.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"1332_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11010-011-1085-x","volume":"361","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X, et al. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating survivin. Mol Cell Biochem. 2012;361(1\u20132):39\u201345.","journal-title":"Mol Cell Biochem"},{"key":"1332_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.carbpol.2015.10.080","volume":"137","author":"CP Dora","year":"2016","unstructured":"Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S, et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2016;137:339\u201349.","journal-title":"Carbohydr Polym"},{"issue":"9","key":"1332_CR13","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/03639045.2017.1326931","volume":"43","author":"KM Yang","year":"2017","unstructured":"Yang KM, Shin IC, Park JW, Kim K-S, Kim DK, Park K, et al. Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm. 2017;43(9):1557\u201365.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"1332_CR14","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1208\/s12249-017-0743-z","volume":"18","author":"S Elkadi","year":"2017","unstructured":"Elkadi S, Elsamaligy S, Al-Suwayeh S, Mahmoud H. The development of self-nanoemulsifying liquisolid tablets to improve the dissolution of simvastatin. AAPS PharmSciTech. 2017;18(7):2586\u201397.","journal-title":"AAPS PharmSciTech"},{"key":"1332_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.colsurfb.2015.09.014","volume":"136","author":"J Shokri","year":"2015","unstructured":"Shokri J, Adibkia K, Javadzadeh Y. Liquisolid technology: what it can do for NSAIDs delivery? Colloids Surf B: Biointerfaces. 2015;136:185\u201391.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"51","key":"1332_CR16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25671","volume":"9","author":"VT Cheriyan","year":"2018","unstructured":"Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, et al. A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget. 2018;9(51):29680.","journal-title":"Oncotarget"},{"key":"1332_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejps.2017.10.007","volume":"111","author":"J Perrier","year":"2018","unstructured":"Perrier J, Zhou Z, Dunn C, Khadra I, Wilson CG, Halbert G. Statistical investigation of the full concentration range of fasted and fed simulated intestinal fluid on the equilibrium solubility of oral drugs. Eur J Pharm Sci. 2018;111:247\u201356.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"1332_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1208\/s12249-017-0885-z","volume":"19","author":"S Kutlehria","year":"2018","unstructured":"Kutlehria S, Behl G, Patel K, Doddapaneni R, Vhora I, Chowdhury N, et al. Cholecalciferol-PEG conjugate based nanomicelles of doxorubicin for treatment of triple-negative breast cancer. AAPS PharmSciTech. 2018;19(2):792\u2013802.","journal-title":"AAPS PharmSciTech"},{"issue":"12","key":"1332_CR19","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1002\/jps.24637","volume":"104","author":"K Patel","year":"2015","unstructured":"Patel K, Chowdhury N, Doddapaneni R, Boakye CHA, Godugu C, Singh M. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J Pharm Sci. 2015;104(12):4417\u201326.","journal-title":"J Pharm Sci"},{"key":"1332_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jconrel.2016.05.017","volume":"246","author":"CHA Boakye","year":"2017","unstructured":"Boakye CHA, Patel K, Doddapaneni R, Bagde A, Marepally S, Singh M. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J Control Release. 2017;246:120\u201332.","journal-title":"J Control Release"},{"issue":"2","key":"1332_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1208\/s12249-015-0370-5","volume":"17","author":"DH Truong","year":"2016","unstructured":"Truong DH, Tran TH, Ramasamy T, Choi JY, Lee HH, Moon C, et al. Development of solid self-emulsifying formulation for improving the oral bioavailability of erlotinib. AAPS PharmSciTech. 2016;17(2):466\u201373.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2008-2231-21-27","volume":"21","author":"K Patel","year":"2013","unstructured":"Patel K, Sarma V, Vavia P. Design and evaluation of Lumefantrine\u2014oleic acid self nanoemulsifying ionic complex for enhanced dissolution. Daru. 2013;21(1):27.","journal-title":"Daru"},{"issue":"6","key":"1332_CR23","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1021\/acs.molpharmaceut.7b00167","volume":"14","author":"J Brus","year":"2017","unstructured":"Brus J, Albrecht W, Lehmann F, Geier J, Czernek J, Urbanova M, et al. Exploring the molecular-level architecture of the active compounds in liquisolid drug delivery systems based on mesoporous silica particles: old tricks for new challenges. Mol Pharm. 2017;14(6):2070\u20138.","journal-title":"Mol Pharm"},{"issue":"12","key":"1332_CR24","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1007\/s11095-013-1114-4","volume":"30","author":"SG Gumaste","year":"2013","unstructured":"Gumaste SG, Pawlak SA, Dalrymple DM, Nider CJ, Trombetta LD, Serajuddin AT. Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on tableting properties and surface structures of different silicates. Pharm Res. 2013;30(12):3170\u201385.","journal-title":"Pharm Res"},{"issue":"8","key":"1332_CR25","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/jps.21650","volume":"98","author":"J Brouwers","year":"2009","unstructured":"Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549\u201372.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1332_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","volume":"13","author":"C Liu","year":"2016","unstructured":"Liu C, Chen Z, Chen Y, Lu J, Li Y, Wang S, et al. Improving oral bioavailability of Sorafenib by optimizing the \u201cspring\u201d and \u201cparachute\u201d based on molecular interaction mechanisms. Mol Pharm. 2016;13(2):599\u2013608.","journal-title":"Mol Pharm"},{"issue":"6","key":"1332_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1208\/s12248-015-9825-6","volume":"17","author":"DD Sun","year":"2015","unstructured":"Sun DD, Lee PI. Haste makes waste: the interplay between dissolution and precipitation of supersaturating formulations. AAPS J. 2015;17(6):1317\u201326.","journal-title":"AAPS J"},{"issue":"3","key":"1332_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0091270005284193","volume":"46","author":"P Frohna","year":"2006","unstructured":"Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46(3):282\u201390.","journal-title":"J Clin Pharmacol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1332-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1332-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T22:07:38Z","timestamp":1593209258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1332-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1332-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"13 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"135"}}